Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Misses Revenue Estimates

Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus Estimate of a loss of $0.71. This compares to a loss of $0.82 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -26.76%. A quarter ago, it was expected that this company would post a loss of $0.83 per share when it actually produced a loss of $0.95, delivering a surprise of -14.46%.Over the last four quarters, the company ...